Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial

Table 2 Hormonal results expressed as median (interquartile range, IQR) values

Treatment	n	Baseline median (IQR)	n	6 months median (IQR)	n	Median change (6 m vs baseline, IQR)	p-value^a
Testosterone, nmol/L
DMPA	131	0.82 (0.56, 1.2)	132	0.68 (0.5, 0.88)	131	−0.16 (− 0.35, 0.04)	< 0.001
IUD	135	0.9 (0.66, 1.18)	135	0.86 (0.68, 1.11)	135	0.01 (−0.19, 0.14)	0.337
Implant	135	0.87 (0.64, 1.26)	135	0.66 (0.51, 0.85)	133	−0.23 (−0.48, − 0.03)	< 0.001
Sex Hormone Binding Globulin, nmol/L
DMPA	131	52.4 (38.4, 74.1)	132	40.65 (31.55–53.9)	131	−9.6 (−21.8, 0.4)	< 0.001
IUD	135	50.5 (34.7, 76)	135	49.1 (36.2–71.1)	135	3 (−13, 15.5)	0.618
Implant	132	55.75 (34.45, 81.9)	134	23.35 (18.1–33.6)	132	−27.2 (−45.85, −12.05)	< 0.001
Free testosterone, pmol/L
DMPA	131	10 (7, 16)	131	11 (8, 15)	131	0 (−3, 3)	0.516
IUD	135	12 (9, 16)	135	12 (9, 17)	135	0 (−4, 2)	0.225
Implant	136	11 (8, 16)	132	14 (10, 18.5)	132	3 (−1.5, 6)	<0.001

^a p-value from Wilcoxon signed-rank test for difference between baseline and six-month values. DMPA, Depot medroxyprogesterone acetate, IUD Copper intrauterine device, Implant – levonorgestrel implant

ISSN: 1472-6874